Peripheral Biomarkers in Neurodegenerative Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 59668
Special Issue Editors
Interests: Alzheimer's disease; oxidative stress; glutamate excitotoxicity in AD
Special Issues, Collections and Topics in MDPI journals
Interests: systems neuroscience; brain oscillations; hippocampus; memory processing; attention
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
The knowledge of neurodegenerative diseases has been circumscribed for many years to its clinical aspects and, in some cases, to different therapeutic attempts. Close to twenty years ago, little was known about the causes of these diseases and of their production mechanisms. The progress made in recent years has been very positive, and new avenues of investigation are being opened. Today we know that neurodegenerative diseases are mainly the consequence of abnormalities in the process of certain proteins, which gives rise to their accumulation in neurons or in their vicinity, diminishing or canceling their functions. The discovery of these proteins has allowed their use as molecular or imaging markers of these diseases, such as beta-amyloid in the case of Alzheimer's. Therefore, the use of biomarkers in the diagnosis of neurodegenerative diseases has increased in recent years. Biomarkers are events found in the human body that are used to identify a biological state. Clinically they are very useful to determine the risk, presence, and severity of a disease. Cerebrospinal fluid (CSF) is the most common source of molecular biomarkers in neurodegeneration. On the other hand, neuroimaging also provides important information about the affected brain areas. Among these biomarkers, those which are involved with neuroimaging are usually expensive and their affordability is frequently limited. CSF biomarkers are sensitive and specific, but their use is limited because a lumbar puncture is required and thus they can cause side effects.
Given the impact of dementia on the global population, the scientific community has driven itself into the quest of finding new biomarkers whose availability is easier for both patients and clinicians. Therefore, the option was to search for new blood-borne biomarkers. Moreover, due to the lower price and reduced invasiveness, a peripheral biomarker can also provide the chance to serve as a screening test to help the diagnosis of neurodegeneration and to monitor progression and response to a hypothetical treatment.
The purpose of this Special Issue is to collect recent information about peripheral biomarkers in neurodegenerative diseases such as Parkinson's, Alzheimer's, Lewy bodies dementia, multiple sclerosis, frontal dementia, Huntington disease, and others. Papers about molecules useful for diagnosis, evolution, prevention, and risk factors are welcome. We invite authors to contribute original research articles as well as review articles exploring peripheral biomarkers in neurodegeneration. Potential topics include but are not limited to the following:
- microRNAs, proteins, and lipids as peripheral biomarkers of Alzheimer’s, Parkinson’s, Huntington, etc.
- Oxidized or inflammation-related molecules as markers of any neurodegenerative disease.
- New CSF molecules as biomarkers of neurodegenerative diseases.
- Neuroimaging and neuronal activity as biomarkers of neurodegenerative diseases.
Dr. Ana Lloret
Dr. Ana Cervera
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- Parkinson disease
- Huntington disease
- amyotrophic lateral sclerosis
- Friedreich’s ataxia
- Lewy bodies dementia
- spinal muscular atrophy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.